Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2007 07:59 ET | Source: Tikvah Therapeutics, Inc.

Tikvah Therapeutics to Present At Lazard Capital Markets Healthcare Conference On November 27

ATLANTA, Nov. 16, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., an Atlanta, GA-based biopharmaceutical company focused on new treatment options to better manage central nervous system diseases,...
November 01, 2007 07:59 ET | Source: Tikvah Therapeutics, Inc.

Tikvah Therapeutics Selected for 'Main-Stage' Presentation At the Ninth Annual Southeastern BIO Investor Forum

ATLANTA, Nov. 1, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., an Atlanta, GA-based biopharmaceutical company focused on new treatment options to better manage central nervous system diseases,...
September 05, 2007 08:00 ET | Source: Tikvah Therapeutics, Inc.

Tikvah Therapeutics, Inc. and Chakra Biotech Pte. Ltd. Establish Collaboration to Accelerate the Development of Novel Antipsychotic Compounds

ATLANTA and SINGAPORE, Sept. 5, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, and...
August 29, 2007 08:00 ET | Source: Tikvah Therapeutics, Inc.

Tikvah Therapeutics Signs Agreement to Develop and Commercialize LY156735, a Second Generation Melatonin Agonist, for Circadian Rhythm and Sleep Disorders

ATLANTA, Aug. 29, 2007 (PRIME NEWSWIRE) -- Atlanta-based Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases,...
August 28, 2007 13:00 ET | Source: Tikvah Therapeutics, Inc.

Families of SMA and Tikvah Therapeutics, Inc. Establish Collaboration to Test Potential Treatment for Spinal Muscular Atrophy

LIBERTYVILLE, Ill. and ATLANTA, Aug. 28, 2007 (PRIME NEWSWIRE) -- Families of Spinal Muscular Atrophy (FSMA) and Tikvah Therapeutics, Inc. today announced that they have established a collaboration to...
August 22, 2007 08:00 ET | Source: Tikvah Therapeutics, Inc.

Dr. Garratt W. Ponder Named Vice President of Pharmaceutical Development for Atlanta-Based Tikvah Therapeutics, Inc.

ATLANTA, Aug. 22, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc. has appointed Dr. Garratt W. Ponder Vice President of Pharmaceutical Development. Dr. Ponder joins Tikvah Therapeutics with over...
August 20, 2007 08:00 ET | Source: Tikvah Therapeutics, Inc.

FDA Grants Tikvah Therapeutics, Inc. Orphan Drug Status for Sodium Phenylbutyrate for the Treatment of Spinal Muscular Atrophy

ATLANTA, Aug. 20, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today...
August 09, 2007 08:00 ET | Source: Tikvah Therapeutics, Inc.

Tikvah Therapeutics Names Jack W. Callicutt Vice President and Chief Financial Officer

ATLANTA, Aug. 9, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today the...
August 07, 2007 08:00 ET | Source: Tikvah Therapeutics, Inc.

Tikvah Therapeutics Licenses Unique Solution Formulations Useful in the Treatment of Neurodegenerative Diseases, Including Spinal Muscular Atrophy, From Navinta, LLC

ATLANTA, Aug. 7, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc. (Tikvah), a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, and Ewing,...
August 02, 2007 08:00 ET | Source: Tikvah Therapeutics, Inc.

Tikvah Therapeutics Names Nathan Andrew Shapira, M.D., Ph.D. Executive Director of Clinical Research and Development and Deputy Chief Medical Officer

ATLANTA, Aug. 2, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today the...